Why must the Bowmed Ibisqus Limited co-amoxiclav 500/100 mg injection/infusion product not be mixed with aminoglycosides in a syringe, intravenous fluid container or giving set?

When prescribed concomitantly, the Bowmed Ibisqus Limited co-amoxiclav 500/100 mg injection/infusion product should not be mixed with an aminoglycoside in a syringe, intravenous fluid container or giving set because loss of aminoglycoside activity can occur.